{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:29:46Z","timestamp":1783686586739,"version":"3.55.0"},"reference-count":35,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review pharmacokinetics, efficacy, and safety of tralokinumab in treatment of atopic dermatitis (AD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>Literature review was conducted using MEDLINE (PubMed), EMBASE, and ClinicalTrials.gov for articles published between January 2010 and May 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction<\/jats:title>\n                    <jats:p>Articles in English discussing tralokinumab in AD were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis<\/jats:title>\n                    <jats:p>In one phase 2 trial, more subjects treated with tralokinumab 150 and 300 mg achieved an Investigator\u2019s Global Assessment (IGA) of 0\/1 with minimum \u22652 point IGA reduction (23%), versus placebo (11.8%, P = 0.10). During 2 phase 3 trials, more subjects treated with tralokinumab achieved IGA success (ECZTRA 1: 15.8% and ECZTRA 2: 22.2%), versus placebo (7.1% and 10.9%, respectively; P = 0.002 and P &lt; 0.001). During one phase 3 trial, in conjunction with topical corticosteroids (TCS), more subjects treated with tralokinumab 300 mg achieved IGA success (ECZTRA 3: 38.9%), versus placebo (26.2%, P = 0.015). During another phase 3 trial in subjects with resistance or contraindication to oral cyclosporine, more subjects treated with tralokinumab 300 mg achieved an Eczema Area Severity Index 75 (64.2%), versus placebo (50.5%, P = 0.018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice<\/jats:title>\n                    <jats:p>Tralokinumab is efficacious for moderate-to-severe AD, as monotherapy, in conjunction with TCS, and resistance or contraindication to cyclosporine. Although IL-4 and IL-13 are both implicated in AD\u2019s pathogenesis, IL-13 is overexpressed, and head-to-head trials are needed to assess efficacy of tralokinumab, versus dupilumab. Compared with upadacitinib and abrocitinib, tralokinumab is not associated with black-box warnings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tralokinumab is an efficacious and safe systemic treatment for moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221105686","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T05:16:36Z","timestamp":1655874996000},"page":"333-340","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Review of Tralokinumab in the Treatment of Atopic Dermatitis"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6532-1639","authenticated-orcid":false,"given":"Rohan","family":"Singh","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-4013","authenticated-orcid":false,"given":"Alexandra","family":"Taylor","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milaan A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay C.","family":"Strowd","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"bibr1-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.06.044"},{"key":"bibr2-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00613-8"},{"issue":"10","key":"bibr3-10600280221105686","first-page":"590","volume":"101","author":"Frazier W","year":"2020","journal-title":"Am Fam Physician"},{"key":"bibr4-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01135-9"},{"key":"bibr5-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0170-1"},{"key":"bibr6-10600280221105686","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S287638"},{"key":"bibr7-10600280221105686","unstructured":"Highlights of prescribing information: ABDRYTM (traloki-numab-ldrm) injection. Accessed April 6, 2022. www.fda.gov\/medwatch."},{"key":"bibr8-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005"},{"key":"bibr9-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022"},{"key":"bibr10-10600280221105686","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S211032"},{"key":"bibr11-10600280221105686","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300300"},{"key":"bibr12-10600280221105686","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3810"},{"key":"bibr13-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"bibr14-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"bibr15-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.018"},{"key":"bibr16-10600280221105686","author":"Guttman-Yassky E","year":"2021","journal-title":"American Academy of Dermatology Association Virtual Meeting Experience (AAD VMX)"},{"key":"bibr17-10600280221105686","unstructured":"European Medicines Agency. Summary of product characteristics: adtralza 150 mg solution for injection in pre-filled syringe. Accessed April 8, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adtralza-epar-product-information_en.pdf."},{"key":"bibr18-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.032"},{"key":"bibr19-10600280221105686","unstructured":"European Medicines Agency. Accessed April 8, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/adtralza."},{"key":"bibr20-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03647.x"},{"key":"bibr21-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"bibr22-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.004"},{"key":"bibr23-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"bibr24-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19573"},{"key":"bibr25-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20832"},{"key":"bibr26-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.650"},{"issue":"8","key":"bibr27-10600280221105686","first-page":"925","volume":"15","author":"Matsunaga MC","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"bibr28-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.047"},{"key":"bibr29-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08934-0"},{"key":"bibr30-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.031"},{"key":"bibr31-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.051"},{"key":"bibr32-10600280221105686","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"bibr33-10600280221105686","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e3015"},{"key":"bibr34-10600280221105686","unstructured":"Highlights of prescribing information: CIBINQO\n                      TM\n                      (abrocitinib) tablets. Accessed April 6, 2022. www.fda.gov\/medwatch."},{"key":"bibr35-10600280221105686","unstructured":"Highlights of prescribing information: RINVOQ\n                      TM\n                      (upadacitinib) tablets. Accessed April 6, 2022. www.fda.gov\/medwatch."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221105686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221105686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221105686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:56Z","timestamp":1777375016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221105686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10600280221105686"],"URL":"https:\/\/doi.org\/10.1177\/10600280221105686","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}